Sat. Jul 20th, 2024 online news,India,June 26, 2024:Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY; along with its subsidiaries together referred to as “Dr. Reddy’s”), a global pharmaceutical company, today announced that its subsidiary Dr. Reddy’s Laboratories SAhas signed a definitive agreement with Haleonplc (LSE/NYSE: HLN; “Haleon”), a leading consumer healthcare company, for purchase of shares of Northstar Switzerland SARL, a Haleon group company,to acquire Haleon’s global portfolio of consumer healthcare brands in the Nicotine Replacement Therapy (“NRT”) category outside of the United States.

The portfolio to be acquired consists of Nicotinell, a global leader in the NRT category withan extensive footprint in over 30 countries spanning Europe, Asia including Japan, and Latin America, and local market-leading brand names of the product – Nicabate in Australia, Thrive in Canada, and Habitrol in New Zealand and Canada.

The proposed acquisition will be inclusive of all formats such as lozenge, patch, gum as well as pipeline products, in all applicable global markets outside of the United States.

Nicotinell is the second biggest brand globally (excluding the United States) in the NRT category. It holds the first or second position in 14 of the top 17 global markets, with the lozenge/mini lozenge format holding top position globally.

Nicotinell ranksamong the top 15 biggest brands among all OTC brands in Europe (excluding Russia, Italy), and ranks 32 among all OTC global brands (excluding the U.S.). In CY’23, the portfolio generated approximately GBP 217 million in revenue.

Dr. Reddy’s will acquire the share capital of Northstar Switzerland SARL for a total consideration of GBP 500 million with an upfront cash payment of GBP 458 million and performance-based contingent payments of up to GBP 42 million, payable in 2025 and 2026.

The closing of the transaction is subject to satisfactory completion of customary conditions to closing, including regulatory approvals. The transaction is expected to close inearly Q4 of calendar year 2024.

Upon closing of the transaction, Dr. Reddy’s will acquire the NRT business in all countries outside of the United States. However, operations will transition to Dr. Reddy’s in a phased approach to ensure successful integration of the business.

Tobacco use causes eight million deaths every year from health consequences such as cardiovascular diseases, lung disorders, cancers, diabetes, and many other debilitating diseases.According to the World Health Organization (“WHO”),of the 1.3 billion tobacco users globally, as many as 60% have expressed the desire to quit; however only 30% have access to the tools to help them to do so successfully.Safe and effective medical treatments to help individuals quit tobacco are available, but not always sufficiently available or accessible.

NRT is recommended by the ‘World Health Organization Model List of Essential Medicines’ for nicotine use disorders. NRT also played a key role in the WHO’s ‘Access Initiative for Quitting Tobacco’ launched in 2020 to help tobacco users quit to reduce the risk of severe outcomes from COVID-19 infection.

In line with its stated strategic intention, Dr. Reddy’s continues to focus on its core business of generics, branded generics, Active Pharmaceutical Ingredients (API), over-the-counter (OTC) products, and biosimilars.Alongside this, the company has been investing in growth drivers of the future in three areas– accessto novel molecules (NCEs, NBEs, CAR-T); digital therapeutics (wearables, apps); and consumer healthcare (including nutrition and OTC wellness products).

As part of its consumer healthcare OTC business in the United States, Dr. Reddy’s has in recent years acquired several well-known brands such as the NRT brand Habitrol, pain-relief brand Doan’s, women’s health products such as Premama for fertility and parenthood, and the MenoLabs portfolio for menopause. In India, Dr. Reddy’s has a portfolio of OTC products in the hydration, cough-cold-allergy, and skin care categories.

The recent announcement of a joint venture with Nestlé India to bring the well-known global range of nutritional health solutions as well as vitamin, minerals, herbals and supplements of Nestlé Health Science (NHSc) to India, is another significant move to strengthen its nutrition and OTC business in India.In Emerging Markets, Dr. Reddy’s has a long-established and sizeable OTC business with market-leading products in the allergy, pain relief, gastro-intestinal and women’s health categories in Russia & CIS, South Africa, Asia, Latin America & the Caribbean.

Earlier this year, Dr. Reddy’s entered the UK consumer health market with the launch of the allergy medication Histallay.With increasing presence in consumer health and OTC in global markets, the company has been strengthening its capabilities in brand-building, marketing, digital and analytics, including exploring e-commerce partnerships.

The latest proposed acquisition of Nicotinell and related portfolio gives Dr. Reddy’s a strong footprint in Europe as well as other global markets, complementing and building on its existing global presence and capabilities.

Erez Israeli, Chief Executive Officer of Dr. Reddy’s, said: “We see the acquisition of this global portfolio of consumer healthcare products led by the global brand Nicotinell as a logical extension of our efforts in consumer healthcare OTC in recent years, and of our purpose of ‘Good Health Can’t Wait’.

We have been steadily building our OTC presence in various markets and investing in our capabilities. As a business, consumer healthcare is a growing and sustainable business with favourable long-term trends. The business to be acquired from Haleon has maintained steady sales and strong profitability over the years.

The portfolio is attractive for its customer loyalty, itsglobal nature, and the access it provides to key customers. We believe we can unlock more value, grow the portfolio further, and increase consumer access around the world to these global brands.Given these advantages, it is the ideal anchor around which to build a larger global OTC platform.”

Also read :MSME Day: How Financial Institutions Can Drive Holistic Growth of Small Businesses

Also read :Bank’s Senior Unsecured Long Term Bond Issuance

ఇదికూడా చదవండి: జీహెచ్ఎంసీ ఎన్ఫోర్స్మెంట్, విజిలెన్స్ అండ్ డిజాస్టర్ మేనేజ్మెంట్ కమిషనర్ గా బాధ్యతలు చేపట్టిన ఏ.వి. రంగనాథ్

Also read :HDFC Bank Empowers MSMEs with Special Knowledge Sessions

ఇదికూడా చదవండి: పలు ప్రాంతాల్లో నేడు, రేపు నీటి సరఫరాలో అంతరాయం..

Also read :CII Telangana organized the 6th edition of its flagship CFO Conclave

Also read :Udyog Plus emerges as a strong MSME lending platform

ఇదికూడా చదవండి:జీ5తో కలిసి మరింత వినోదాన్ని అందించనున్న వీ మూవీస్ & టీవీ యాప్..

Also read :Vi Movies & TV App Zee5 offers entertainment with access to 17 OTT apps vidudala new subscription plans